Bottom line
What is PHLCX's expense ratio?
PHLCX's expense ratio is 1.97%, or about $197 a year on every $10,000 invested. That is more expensive than 94% of health care sector funds we track (median 0.96%). It has no front-end sales load. Its expense ratio includes a 1% 12b-1 marketing fee.
Updated Jan 28, 2026
PHLCX fee table
| Net expense ratio | 1.97% |
|---|---|
| Gross expense ratio | 1.97% |
| Management fee | 0.73% |
| 12b-1 (distribution) fee | 1% |
| Other expenses | 0.24% |
| Fee waiver / reimbursement | 0% |
| Max front-end sales load | 0% |
| Max deferred sales charge | 1% |
| Redemption fee | 0% |
Source: Fund prospectus fee table, filed Jan 28, 2026
What PHLCX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| PHLCX | $300 | $618 | $1,062 | $2,084 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.97% expense ratio costs roughly $100,300 in lost growth, versus about $53,400 for the median health care sector fund (0.96%).
Cheaper alternatives to PHLCX
These funds have a similar portfolio (by top-holdings overlap) and a lower expense ratio. Savings are per $10,000 invested.
| Fund | Expense ratio | Saves per year | Saves over 20 yrs* | Overlap |
|---|---|---|---|---|
| PRHSX T. Rowe Price | 0.83% | $114 | $5,367 | 52% |
*Difference in ending value of $10,000 after 20 years at a 6% gross annual return, net of each fund's expense ratio.